BARI, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.552
EU - Europa 4.755
AS - Asia 4.552
SA - Sud America 727
Continente sconosciuto - Info sul continente non disponibili 182
AF - Africa 170
OC - Oceania 35
Totale 22.973
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.280
GB - Regno Unito 1.802
SG - Singapore 1.337
CN - Cina 1.159
IT - Italia 916
BR - Brasile 540
HK - Hong Kong 538
VN - Vietnam 491
DE - Germania 432
SE - Svezia 357
FR - Francia 286
BD - Bangladesh 257
FI - Finlandia 204
RU - Federazione Russa 193
UA - Ucraina 184
TR - Turchia 165
CA - Canada 142
IN - India 109
KR - Corea 103
ID - Indonesia 75
BG - Bulgaria 72
AR - Argentina 62
MA - Marocco 56
MX - Messico 53
JP - Giappone 45
IQ - Iraq 43
ZA - Sudafrica 43
PL - Polonia 36
BE - Belgio 33
ES - Italia 33
PK - Pakistan 32
AU - Australia 31
IE - Irlanda 31
LT - Lituania 31
EC - Ecuador 30
NL - Olanda 28
SA - Arabia Saudita 27
AT - Austria 26
CO - Colombia 26
PH - Filippine 25
AE - Emirati Arabi Uniti 22
CL - Cile 20
CZ - Repubblica Ceca 20
UZ - Uzbekistan 17
CR - Costa Rica 14
JM - Giamaica 14
KE - Kenya 14
IR - Iran 13
JO - Giordania 13
MY - Malesia 13
VE - Venezuela 13
CH - Svizzera 11
PY - Paraguay 11
EG - Egitto 10
AZ - Azerbaigian 9
BO - Bolivia 9
PT - Portogallo 9
DZ - Algeria 7
GR - Grecia 7
KG - Kirghizistan 7
NO - Norvegia 7
PE - Perù 7
UY - Uruguay 7
BH - Bahrain 6
DO - Repubblica Dominicana 6
EU - Europa 6
IL - Israele 6
KZ - Kazakistan 6
NI - Nicaragua 6
NP - Nepal 6
RO - Romania 6
SV - El Salvador 6
ET - Etiopia 5
HU - Ungheria 5
LB - Libano 5
RS - Serbia 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
TZ - Tanzania 5
AL - Albania 4
BZ - Belize 4
GH - Ghana 4
GP - Guadalupe 4
GT - Guatemala 4
NG - Nigeria 4
NZ - Nuova Zelanda 4
PA - Panama 4
PS - Palestinian Territory 4
TN - Tunisia 4
CI - Costa d'Avorio 3
HN - Honduras 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
CY - Cipro 2
DM - Dominica 2
EE - Estonia 2
HR - Croazia 2
MT - Malta 2
PR - Porto Rico 2
Totale 22.763
Salva come PNG Salva come JPEG
Città #
Ashburn 1.575
Southend 1.448
Fairfield 1.059
Santa Clara 964
Singapore 846
Woodbridge 702
San Jose 553
Hong Kong 528
Houston 510
Chandler 497
Seattle 451
Wilmington 401
Cambridge 380
Council Bluffs 358
Ann Arbor 327
Jacksonville 316
Beijing 275
Dearborn 261
Hefei 252
Nyköping 246
Chicago 224
Los Angeles 219
London 193
Modena 183
New York 170
Ho Chi Minh City 155
Milan 135
Helsinki 132
Hanoi 111
San Diego 106
Seoul 98
Shanghai 98
The Dalles 98
Frankfurt am Main 95
São Paulo 86
Salt Lake City 82
Princeton 76
Buffalo 71
Moscow 70
Sofia 70
Columbus 69
Izmir 64
Munich 62
Eugene 61
Dallas 59
Boardman 55
Jakarta 55
Lauterbourg 52
Toronto 43
Casablanca 42
Rome 41
Phoenix 38
Bologna 37
Bremen 35
Elk Grove Village 34
Montreal 33
Redwood City 33
Fremont 31
Warsaw 30
Tampa 29
Tokyo 29
Brussels 28
Da Nang 28
Falls Church 27
Dublin 26
Miami 26
North Bergen 25
Orem 24
Atlanta 22
Johannesburg 22
Brooklyn 20
Denver 20
Dong Ket 20
Sterling 19
Turku 19
Dhaka 17
Lancaster 17
Nanjing 17
Norwalk 17
Rio de Janeiro 17
Chengdu 16
Des Moines 16
Newark 16
Baghdad 15
Guangzhou 15
Nuremberg 15
Paris 15
Philadelphia 15
Poplar 15
Charlotte 14
Guayaquil 14
Naples 14
Washington 14
Boston 13
Brasília 13
Detroit 13
Mexico City 13
Nairobi 13
San Giuliano Milanese 13
Stockholm 13
Totale 16.049
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 638
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 567
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 548
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 514
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 486
The undergraduate nursing student evaluation of clinical learning environment: an Italian survey [La valutazione dell'ambiente di apprendimento clinico da parte degli studenti del Corso di Laurea in Infermieristica: una indagine italiana] 485
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 475
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit 459
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 454
Empathic attitudes among nursing students: a preliminary study 437
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 432
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 422
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 406
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 402
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) 400
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 393
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 389
Activity of BKM120 and BEZ235 against lymphoma cells 387
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 381
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 373
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 365
A concise review of lenalidomide therapy for follicular lymphoma 360
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 350
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 347
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 347
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 344
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 341
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 337
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 337
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 334
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 332
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 330
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 330
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: A phase III randomized study by the fondazione Italiana linfomi 327
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 325
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 323
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 312
Rapid loss of response after withdrawal of treatment with azacitidine: A case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 310
Genomic profiling of enzastaurin-treated B cell lymphoma RL cells 304
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 303
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 303
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma 303
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 300
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 296
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 294
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 292
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial 288
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 282
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 282
Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) 276
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 270
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 269
Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? 264
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 248
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 243
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: Results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL) 240
NATURAL HISTORY OF CRYOGLOBULINEMIA FROM 2000 TO 2018 FROM THE LABORATORY POINT OF VIEW: AN ANALYSIS OF CRYOGLOBULIN CHARACTERISTICS IN A SINGLE CENTER. 236
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 233
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi 211
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 203
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi 203
Khorana score and histotype predicts incidence of early venous thromboembolism in Non-Hodgkin lymphomas: A Pooled-Data analysis of 12 clinical trials of fondazione italiana linfomi (FIL) 202
Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi 198
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis 192
Diagnosi di crioproteinemia: preziosa collaborazione tra laboratorio e clinica per la corretta gestione di una patologia rara 192
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study 165
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature 154
Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma. A Systematic Review by the Fondazione Italiana Linfomi 130
The impact of healthy lifestyles on late sequelae in classical hodgkin lymphoma and diffuse large b-cell lymphoma survivors. A systematic review by the fondazione italiana linfomi 129
Management of adverse events and supportive therapy in relapsed/refractory multiple myeloma 127
Correction to: The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of pet-guided treatments (Annals of Hematology, (2020), 99, 2, (277-282), 10.1007/s00277-019-03893-7) 126
Management of multiple myeloma|Terapia del mieloma multiplo 116
Totale 22.973
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.135
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.135
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.134 0 0 0 64 28 119 83 112 150 112 266 200
2022/20231.396 152 185 113 141 152 196 25 131 180 13 66 42
2023/20241.099 58 38 75 106 232 72 199 101 33 19 63 103
2024/20253.171 104 40 76 245 645 494 220 181 361 119 255 431
2025/20266.668 406 254 440 794 1.106 417 724 390 648 571 503 415
2026/20271.884 165 531 449 739 0 0 0 0 0 0 0 0
Totale 22.973